Insider Transactions in Q1 2023 at Chinook Therapeutics, Inc. (KDNY)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 01
2023
|
Davis Jerel Director |
SELL
Open market or private sale
|
Indirect |
400,000
-13.23%
|
$8,800,000
$22.75 P/Share
|
|
Feb 10
2023
|
Tom Frohlich Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,700
-2.4%
|
$85,100
$23.75 P/Share
|
|
Feb 10
2023
|
Tom Frohlich Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,803
+4.22%
|
-
|
|
Feb 10
2023
|
Eric Dobmeier President, CEO |
SELL
Open market or private sale
|
Direct |
8,097
-2.62%
|
$186,231
$23.75 P/Share
|
|
Feb 10
2023
|
Eric Dobmeier President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,248
+6.15%
|
-
|
|
Feb 10
2023
|
Eric Bjerkholt Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
857
-2.16%
|
$19,711
$23.75 P/Share
|
|
Feb 10
2023
|
Eric Bjerkholt Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,435
+5.78%
|
-
|
|
Feb 10
2023
|
Andrew James King Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,392
-10.93%
|
$55,016
$23.75 P/Share
|
|
Feb 10
2023
|
Andrew James King Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,803
+23.71%
|
-
|
|
Jan 31
2023
|
Tom Frohlich Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
4,566
-3.0%
|
$109,584
$24.68 P/Share
|
|
Jan 31
2023
|
Tom Frohlich Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,333
+5.19%
|
-
|
|
Jan 31
2023
|
Andrew James King Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,244
-17.7%
|
$77,856
$24.68 P/Share
|
|
Jan 31
2023
|
Andrew James King Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,333
+31.26%
|
-
|
|
Jan 31
2023
|
Eric Bjerkholt Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,891
-7.2%
|
$69,384
$24.68 P/Share
|
|
Jan 31
2023
|
Eric Bjerkholt Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,333
+15.43%
|
-
|
|
Jan 31
2023
|
Eric Dobmeier President, CEO |
SELL
Open market or private sale
|
Direct |
7,688
-2.59%
|
$184,512
$24.68 P/Share
|
|
Jan 31
2023
|
Eric Dobmeier President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
24,999
+7.77%
|
-
|
|
Jan 30
2023
|
Eric Dobmeier President, CEO |
SELL
Open market or private sale
|
Direct |
25,000
-8.43%
|
$600,000
$24.54 P/Share
|
|
Jan 30
2023
|
Eric Dobmeier President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+7.77%
|
$0
$0.42 P/Share
|
|
Jan 03
2023
|
Andrew James King Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
10,000
-50.02%
|
$250,000
$25.82 P/Share
|
|
Jan 03
2023
|
Andrew James King Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+27.28%
|
$0
$0.35 P/Share
|